ARCHER trial
-
Cardiol Therapeutics’ Cannabidiol Formulation Reduced Inflammation—Phase II Topline Data Ignites the Race to Treat Acute Myocarditis
A single‐digit p-value has rarely carried such freight. Cardiol Therapeutics Inc. (NASDAQ: CRDL | TSX: CRDL) this morning unveiled…
-
Cardiol Furthers Clinical Trials to Advance Disruptive Cannabidiol-Based Therapies for Heart Disease
Heart disease continues to be a leading cause of death globally. According to Cardiol Therapeutics Inc. (NASDAQ: CRDL…
-
Cardiol Therapeutics is concerned with affairs of the heart
One thing I really enjoy about writing for InvestorIntel is all the random learning I get from reading…
